StockNews.com began coverage on shares of Aptose Biosciences (NASDAQ:APTO – Get Free Report) (TSE:APS) in a research report issued to clients and investors on Sunday. The brokerage set a “hold” rating on the biotechnology company’s stock.
Separately, HC Wainwright reiterated a “buy” rating and issued a $2.00 price objective on shares of Aptose Biosciences in a research note on Friday, January 10th.
Read Our Latest Stock Analysis on APTO
Aptose Biosciences Stock Up 3.0 %
Institutional Trading of Aptose Biosciences
An institutional investor recently raised its position in Aptose Biosciences stock. Sigma Planning Corp lifted its position in shares of Aptose Biosciences Inc. (NASDAQ:APTO – Free Report) (TSE:APS) by 71.3% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 401,750 shares of the biotechnology company’s stock after purchasing an additional 167,282 shares during the quarter. Sigma Planning Corp owned 2.22% of Aptose Biosciences worth $165,000 as of its most recent SEC filing. Institutional investors and hedge funds own 26.62% of the company’s stock.
Aptose Biosciences Company Profile
Aptose Biosciences Inc, a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies.
See Also
- Five stocks we like better than Aptose Biosciences
- 3 Home Improvement Stocks that Can Upgrade Your Portfolio
- Merck: 4 No-Brainer Reasons to Buy This Dip
- What is Forex and How Does it Work?
- Ackman Announces Major Stake in Uber: Should You Follow His Lead?
- Trading Stocks: RSI and Why it’s Useful
- Wells Fargo Upgraded These 3 Stocks—Here’s Why They Stand Out
Receive News & Ratings for Aptose Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aptose Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.